1966 Leland Clark and Frank Gollan demonstrated that spontaneously breathing mice survive when submerged in PFC.
1974 Thomas Shaffer and Gordon Moskowitz developed demand-regulated liquid ventilation.
1976 Thomas Shaffer, David Rubinstein, Gordon Moskowitz, and Maria Delivoria-Papadopoulos demonstrated that gas exchange and acid-base balance in premature lambs improved during liquid ventilation.
1983 Thomas Shaffer, Patricia Douglas, Corinne Lowe, Vinod Bhutani demonstrate improved gas exchange and lung compliance in preterm lambs during liquid ventilation.
1989 Jay Greenspan,  Marla Wolfson, David Rubinstein and Thomas Shaffer conducted the first human Liquid Ventilation trial with premature infants. These studies demonstrated that there is  improvement in lung mechanics and gas exchange during liquid ventilation with perfluorochemical fluid.
1992 Marla Wolfson, Jay Greenspan, Kiran Deoras, David Rubenstein and Thomas Shaffer demonstrated that elimination of surface active forces by liquid ventilation provides more effective gas exchange with less barotrauma compared with gas ventilation.
1994 Marla Wolfson, Robert Stern, Nancy Kechner, Michael Sekins, and Thomas Shaffer demonstrate the utility of a highly radiopaque perfluorochemical liquid in combination with diagnostic imaging techniques to visualize small airways anatomy, identify regional and gravity dependent differences in distribution/elimination of the fluid, ventilation, and track perfluorochemical liquid following therapeutic application.
1994 William Fox, Carla Weis, Marla Wolfson and Thomas Shaffer evaluated the effects of the physical properties of density and viscosity on airway resistance during liquid ventilation with perfluorochemical fluid.
1996 The LiquiVent Study Group demonstrated in a company sponsored trial that Partial Liquid Ventilation leads to clinical improvement and survival in infants with severe respiratory distress syndrome who are predicted to not survive.
1996 Marla Wolfson, Jay Greenspan and Thomas Shaffer showed that vasoactive agents can be delivered to the lungs during liquid ventilation with perfluorochemical liquid. The inherent advantages of this method relates to the physical properties of perfluorochemical liquid ventilation as a vehicle (respiratory gas solubility, low surface tension-enhancing distribution, and inertness precluding interaction) and physiological properties of the lung as an exchanger.
1996 Robin Steinhorn, Corinne Leach, Bradley Fuhrman, Bruce Holm demonstrated that partial liquid ventilation with perfluorooctylbromide appears to have no negative impact on phospholipid metabolism but rather enhances surfactant phospholipid synthesis and secretion.
1997 William Fox, Carla Weis, Clotilde Farina, Henry Drott, Marla Wolfson, Thomas Shaffer showed perfluorochemical fluid during liquid ventilation provides an effective vehicle for gentamicin delivery in infants with severe pulmonary infection and ventilation/perfusion abnormalities.
1997 Jay Greenspan, William Fox, David Rubenstein, Marla Wolfson, Sue Spinner, Thomas Shaffer, and the Philadelphia Liquid Ventilation Consortium demonstrated that partial liquid ventilation is safe, improves lung function, and recruits lung volume in critically ill infants receiving extracorporeal life support (ECMO).
1997 Duncan Wilcox, Philip Glick, Hratch Karamanoukian, Bruce Morin, Bradley Fuhrman and Corinne Leach showed that liquid ventilation improves gas exchange and pulmonary mechanics in congenital diaphragmatic hernia and allows the effective delivery of nitric oxide to reduce the pulmonary hypertension associated with CDH.
1999 Carla Weis, William Fox, Marla Wolfson, and Thomas Shaffer demonstrated the role of repositioning a baby during liquid ventilation on elimination of perfluorochemical from the lungs.
2000 Mai-Jy Jeng, Daniele Trevisanuto, Carla Weis, William Fox, Marla Wolfson, and Thomas Shaffer evaluated the role of ventilation strategy on perfluorochemical evaporation from the lungs and found that evaporative loss of perfluorochemical during liquid ventilation is dependent on minute ventilation.
2000 Daniele Trevisanuto, Mai-Jy Jeng, Carla Weis, William Fox, Marla Wolfson, and Thomas Shaffer showed that positive end-expiratory pressure (PEEP) modulates perfluorochemical (PFC) evaporation from the lungs
2002 Cindy Cox, William Fox, Carla Weiss, Marla Wolfson, and Thomas Shaffer showed perfluorochemical levels in the blood and tissue are low during liquid ventilation relative to that associated with intravenous administration of perfluorochemical fluid emulsion.
2003 Ronald Hirschl, Willian Fox, Philip Glick, Jay Greenspan, Kendra Smith, Anne Thompson, Jay Wilson, and Scott Adzick  evaluated  PLV and perfluorocarbon-induced lung growth (PILG) in newborns with congenital diaphragmatic hernia on extracorporeal life support and showed that PILG can be performed safely. The survival rate and ventilator free days in the PILG patients were better than the conventional ventilation group.
2011 Jeffrey Kazzaz, Marlene Strayer, Jichuan Wu, Daniel Malone, Hshi-chi Koo, Thomas Shaffer, Jonathan Davis, David Strayer, and Marla Wolfson demonstrated that  PFC-rAdenovirus suspensions improve distribution and enhance rAdenovirus-mediated gene expression which has important implications in improving lung function by gene therapy.
2017 William Fox, Huayan Zang and the CHOP Liquid Ventilation team are currently evaluating the safety of Liquid Ventilation in infants with severe chronic lung disease.
Neonatal Liquid Ventilation